Methotrexate, bleomycin, and Etoposide in the treatment of gestational trophoblastic neoplasia

Obstetrics and Gynecology
Hextan Y S NganKaren K L Chan

Abstract

The combination of methotrexate (1 g/m(2) day 1), bleomycin (10 mg day 3), and etoposide (100 mg/m(2) days 1-5) (MBE) has been used for disease relapse or as a second-line chemotherapy in the treatment of gestational trophoblastic neoplasia (GTN) resistant to multiple-agent chemotherapy. With the identification of ultra-high-risk GTN, MBE has also been used as first-line chemotherapy. The current study is to review the use of MBE in the treatment of GTN. Patients who received MBE for GTN between 1985 and 2003 in Queen Mary Hospital were included in this study. Records were reviewed and data were analyzed. Outcomes including response rate, treatment complications, and survival were assessed. Methotrexate, bleomycin, and etoposide therapy was given as first line to 4 patients with ultra-high-risk GTN. Three responded to the treatment and remained disease free. Methotrexate, bleomycin, and etoposide were given as a second-line therapy to 8 patients who had drug resistance to the initial therapy. Seven responded, and 6 remained disease free at 5 years. Methotrexate, bleomycin, and etoposide were given as a second-line therapy to 8 patients who relapsed 2-18 months after their initial therapy. Seven patients responded, and 4 remaine...Continue Reading

References

Jan 1, 1976·Journal of Clinical Pathology. Supplement (Royal College of Pathologists)·K D Bagshawe
Feb 1, 1991·American Journal of Obstetrics and Gynecology·J R LurainA W Rademaker
Jul 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J RustinK D Bagshawe
Nov 1, 1988·Gynecologic Oncology·G BolisC Mangioni
Jan 1, 1986·British Journal of Obstetrics and Gynaecology·E S NewlandsJ Dent
Jul 1, 1996·Radiology·W SmallW N Brand
Oct 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J RustinD Short
Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M BowerK D Bagshawe
Jun 12, 2002·Current Treatment Options in Oncology·John R Lurain
Jun 18, 2002·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·UNKNOWN FIGO Oncology Committee
Sep 16, 2003·Clinical Obstetrics and Gynecology·Jason D Wright, David G Mutch
May 3, 2005·Gynecologic Oncology·John R Lurain, Bahareh Nejad

❮ Previous
Next ❯

Citations

Feb 18, 2014·Current Obstetrics and Gynecology Reports·Siew-Fei Ngu, Karen K L Chan
May 8, 2007·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Yuyan MaoXing Xie
Jan 31, 2012·Best Practice & Research. Clinical Obstetrics & Gynaecology·K Y Tse, Hextan Y S Ngan
Jan 17, 2012·Hematology/oncology Clinics of North America·Donald Peter Goldstein, Ross S Berkowitz
Aug 25, 2020·American Journal of Obstetrics & Gynecology MFM·Margaux LouchetLaurent Mandelbrot

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.